Fusion protein of human somatostatin 28 peptide and human serum albumin, encoding gene of fusion protein and preparation method for fusion protein

Abstract

The invention discloses fusion protein of human somatostatin 28 peptide and human serum albumin. The fusion protein comprises a first area which is homologous with at least 85 percent of a sequence of the human somatostatin 28 peptide, and a second area which is homologous with at least 85 percent of a sequence of the human serum albumin or a second area containing part of an amino acid sequence of the human serum albumin, wherein the first area which is homologous with the human somatostatin 28 peptide is positioned at an N terminal of the fusion protein, the second area which is homologous with the human serum albumin is positioned at a C terminal of the fusion protein, and connecting peptide is not added between the first area and the second area; or the second area which is homologous with at least 85 percent of the sequence of the human serum albumin is positioned at the N terminal of the fusion protein, the first area which is homologous with at least 85 percent of the sequence of the human somatostatin 28 peptide is positioned at the C terminal of the fusion protein, and connecting peptide is not added between the first area and the second area. The invention has the advantages that the fusion protein can be applied to the treatment of various diseases caused by the excess secretion of growth hormone, and is used for treating diseases caused by the endocrine disorder of gastrointestinal tracts, inhibiting the growth of tumors which express somatostatin receptors (SSTRs) and do not express the SSTRs, and reducing the death rate caused by the radiation injury of the gastrointestinal tracts.

Description

technical field [0001] The invention belongs to the technical field of long-acting fusion protein drugs, and in particular relates to a fusion protein of human somatostatin octacosopeptide and human serum albumin. Background technique [0002] Somatostatin (somatostatin, SST) is a cyclic polypeptide hormone. It is a somatotropin release-inhibiting factor (SRIF) isolated and purified from sheep hypothalamus by Brazeau et al. in 1973. It has 14 Peptide (SST14) and Peptide 28 (SST-28) in two natural forms. SST-28 is the N-terminal extended form of SST14, both of which are proteolytically derived from the same precursor (92-peptide somatostatin precursor). Although the two have similar activities, there are still some differences in their strength of action and histological characteristics. SST14 has a strong inhibitory effect on glucagon and gastrin, while SST-28 has a strong inhibitory effect on growth hormone and insulin. [0003] SST exerts a variety of biological activiti...

AI Technical Summary

Problems solved by technology

Natural SST has a wide range of effects, but its selectivity is poor and its half-life is short. After stopping the drug, it is prone to rebound high secretion of hormone levels, so its clinical application is limited.

Synthetic somatostatin analogues, such as octreotide, vapreotide, lanreotide, and siglipide, have long-lasting but relatively single effects, and only have high affinity with some receptors, and their physiological functions are far inferior to natural ones. SST

Images